| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spinal Neoplasms | 25 | 2024 | 631 | 3.630 |
Why?
|
| Bone Neoplasms | 20 | 2024 | 2576 | 3.160 |
Why?
|
| Chondrosarcoma | 5 | 2023 | 216 | 2.450 |
Why?
|
| Radiosurgery | 22 | 2024 | 1330 | 2.160 |
Why?
|
| Soft Tissue Neoplasms | 8 | 2022 | 882 | 1.880 |
Why?
|
| Chordoma | 5 | 2023 | 163 | 1.560 |
Why?
|
| Multiple Myeloma | 15 | 2024 | 2138 | 1.380 |
Why?
|
| Sarcoma | 10 | 2024 | 1725 | 1.270 |
Why?
|
| Chondroma | 2 | 2020 | 31 | 1.260 |
Why?
|
| Radiology | 7 | 2022 | 434 | 1.250 |
Why?
|
| Magnetic Resonance Imaging | 26 | 2024 | 7702 | 1.230 |
Why?
|
| Diagnostic Imaging | 10 | 2020 | 1162 | 1.220 |
Why?
|
| Fluorodeoxyglucose F18 | 5 | 2020 | 1226 | 1.100 |
Why?
|
| Positron Emission Tomography Computed Tomography | 6 | 2022 | 833 | 1.060 |
Why?
|
| Liposarcoma | 4 | 2022 | 214 | 0.990 |
Why?
|
| Fibromatosis, Aggressive | 3 | 2022 | 109 | 0.860 |
Why?
|
| Ankle | 2 | 2018 | 36 | 0.820 |
Why?
|
| Sarcopenia | 2 | 2021 | 110 | 0.810 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 2021 | 38 | 0.810 |
Why?
|
| Internship and Residency | 4 | 2021 | 1375 | 0.800 |
Why?
|
| Osteosarcoma | 4 | 2022 | 929 | 0.800 |
Why?
|
| Teaching Materials | 2 | 2018 | 21 | 0.790 |
Why?
|
| Spinal Cord Compression | 6 | 2017 | 151 | 0.770 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2020 | 11 | 0.770 |
Why?
|
| Chondroblastoma | 1 | 2020 | 15 | 0.770 |
Why?
|
| Arthralgia | 4 | 2019 | 89 | 0.760 |
Why?
|
| Osteoblastoma | 1 | 2020 | 15 | 0.760 |
Why?
|
| Osteoma, Osteoid | 1 | 2020 | 22 | 0.760 |
Why?
|
| Software | 2 | 2018 | 1321 | 0.750 |
Why?
|
| Spine | 4 | 2022 | 293 | 0.740 |
Why?
|
| Oncologists | 1 | 2022 | 134 | 0.730 |
Why?
|
| Bursitis | 2 | 2017 | 10 | 0.730 |
Why?
|
| Contrast Media | 8 | 2020 | 1472 | 0.710 |
Why?
|
| Radiopharmaceuticals | 6 | 2020 | 1301 | 0.690 |
Why?
|
| Humans | 123 | 2024 | 261506 | 0.690 |
Why?
|
| Shoulder Joint | 2 | 2017 | 82 | 0.680 |
Why?
|
| Appendiceal Neoplasms | 1 | 2021 | 234 | 0.680 |
Why?
|
| Multimodal Imaging | 6 | 2020 | 550 | 0.660 |
Why?
|
| Diagnosis, Differential | 12 | 2021 | 4744 | 0.650 |
Why?
|
| Health Physics | 1 | 2018 | 63 | 0.640 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2021 | 436 | 0.630 |
Why?
|
| Foot | 1 | 2018 | 104 | 0.630 |
Why?
|
| Neoplasm Recurrence, Local | 15 | 2024 | 10035 | 0.630 |
Why?
|
| Bone Diseases | 2 | 2019 | 143 | 0.580 |
Why?
|
| Radiologists | 4 | 2022 | 163 | 0.560 |
Why?
|
| Spinal Fractures | 3 | 2024 | 132 | 0.540 |
Why?
|
| Paraproteinemias | 1 | 2016 | 61 | 0.540 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2024 | 7551 | 0.530 |
Why?
|
| Positron-Emission Tomography | 4 | 2020 | 2173 | 0.530 |
Why?
|
| Laser Therapy | 5 | 2017 | 411 | 0.530 |
Why?
|
| Li-Fraumeni Syndrome | 3 | 2022 | 158 | 0.520 |
Why?
|
| Models, Neurological | 3 | 2005 | 225 | 0.510 |
Why?
|
| Muscle, Skeletal | 4 | 2023 | 1270 | 0.510 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2014 | 34 | 0.510 |
Why?
|
| Acetabulum | 1 | 2014 | 38 | 0.500 |
Why?
|
| Joint Diseases | 1 | 2014 | 71 | 0.480 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 2013 | 37 | 0.460 |
Why?
|
| Action Potentials | 3 | 2005 | 560 | 0.450 |
Why?
|
| Connective Tissue Diseases | 1 | 2013 | 50 | 0.450 |
Why?
|
| Quality Improvement | 1 | 2020 | 851 | 0.430 |
Why?
|
| Computed Tomography Angiography | 3 | 2019 | 234 | 0.410 |
Why?
|
| Multidetector Computed Tomography | 1 | 2013 | 150 | 0.410 |
Why?
|
| Lipoma | 2 | 2023 | 89 | 0.410 |
Why?
|
| Retrospective Studies | 29 | 2024 | 37905 | 0.410 |
Why?
|
| Middle Aged | 47 | 2024 | 86204 | 0.390 |
Why?
|
| Male | 55 | 2023 | 123000 | 0.390 |
Why?
|
| Nuclear Medicine | 1 | 2011 | 46 | 0.380 |
Why?
|
| Chronic Pain | 3 | 2018 | 238 | 0.370 |
Why?
|
| Fractures, Compression | 2 | 2024 | 42 | 0.360 |
Why?
|
| Biomedical Research | 1 | 2017 | 806 | 0.360 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2013 | 261 | 0.360 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2013 | 551 | 0.350 |
Why?
|
| Plasmacytoma | 2 | 2021 | 111 | 0.340 |
Why?
|
| Gadolinium | 2 | 2020 | 164 | 0.340 |
Why?
|
| Hyperthermia, Induced | 4 | 2017 | 510 | 0.330 |
Why?
|
| Aged | 40 | 2023 | 70117 | 0.320 |
Why?
|
| Computer-Assisted Instruction | 2 | 2019 | 81 | 0.320 |
Why?
|
| Biological Clocks | 2 | 2005 | 45 | 0.320 |
Why?
|
| Thigh | 2 | 2021 | 172 | 0.320 |
Why?
|
| Societies, Medical | 9 | 2020 | 1335 | 0.310 |
Why?
|
| Chondrosarcoma, Mesenchymal | 2 | 2018 | 17 | 0.310 |
Why?
|
| Osteoarthritis, Hip | 1 | 2007 | 17 | 0.310 |
Why?
|
| Scapula | 2 | 2019 | 37 | 0.300 |
Why?
|
| Lyme Disease | 1 | 2007 | 34 | 0.300 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 3 | 2017 | 96 | 0.300 |
Why?
|
| Adult | 42 | 2023 | 77950 | 0.300 |
Why?
|
| Methylphenidate | 2 | 2004 | 103 | 0.290 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 2 | 2019 | 301 | 0.280 |
Why?
|
| Sarcoma, Synovial | 2 | 2017 | 119 | 0.270 |
Why?
|
| Female | 46 | 2024 | 141928 | 0.270 |
Why?
|
| Central Nervous System Stimulants | 2 | 2004 | 225 | 0.270 |
Why?
|
| Fractures, Bone | 2 | 2023 | 291 | 0.260 |
Why?
|
| Retroperitoneal Neoplasms | 2 | 2019 | 262 | 0.260 |
Why?
|
| Evidence-Based Medicine | 7 | 2020 | 1085 | 0.260 |
Why?
|
| Hodgkin Disease | 2 | 2024 | 1429 | 0.260 |
Why?
|
| Young Adult | 20 | 2024 | 21445 | 0.250 |
Why?
|
| Phrenic Nerve | 1 | 2004 | 16 | 0.250 |
Why?
|
| Sensitivity and Specificity | 3 | 2020 | 4971 | 0.250 |
Why?
|
| Radiotherapy, Intensity-Modulated | 4 | 2019 | 2104 | 0.240 |
Why?
|
| Emergency Service, Hospital | 2 | 2015 | 1148 | 0.240 |
Why?
|
| Respiratory Mechanics | 1 | 2005 | 173 | 0.240 |
Why?
|
| Radionuclide Imaging | 3 | 2024 | 660 | 0.240 |
Why?
|
| Calcinosis | 2 | 2018 | 423 | 0.240 |
Why?
|
| Benzophenones | 1 | 2023 | 12 | 0.240 |
Why?
|
| Aged, 80 and over | 22 | 2022 | 29902 | 0.240 |
Why?
|
| Free Tissue Flaps | 2 | 2019 | 372 | 0.240 |
Why?
|
| Pedicle Screws | 1 | 2023 | 10 | 0.240 |
Why?
|
| Motor Neurons | 1 | 2004 | 138 | 0.230 |
Why?
|
| Sacrum | 2 | 2023 | 132 | 0.220 |
Why?
|
| Plastics | 1 | 2023 | 93 | 0.220 |
Why?
|
| Neck Injuries | 1 | 2023 | 32 | 0.220 |
Why?
|
| Prognosis | 16 | 2022 | 21713 | 0.220 |
Why?
|
| Treatment Outcome | 20 | 2023 | 32848 | 0.220 |
Why?
|
| Calibration | 2 | 2020 | 337 | 0.210 |
Why?
|
| Nerve Net | 1 | 2005 | 257 | 0.210 |
Why?
|
| Polymers | 1 | 2023 | 223 | 0.210 |
Why?
|
| Spinal Fusion | 1 | 2023 | 149 | 0.210 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2018 | 755 | 0.210 |
Why?
|
| Preoperative Care | 2 | 2019 | 1529 | 0.210 |
Why?
|
| Bone Marrow | 2 | 2020 | 2358 | 0.210 |
Why?
|
| Peritoneal Cavity | 1 | 2021 | 56 | 0.210 |
Why?
|
| Benchmarking | 1 | 2024 | 273 | 0.200 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2022 | 75 | 0.200 |
Why?
|
| Appendix | 1 | 2021 | 41 | 0.200 |
Why?
|
| Motor Activity | 2 | 2004 | 693 | 0.200 |
Why?
|
| Paraproteins | 1 | 2021 | 39 | 0.190 |
Why?
|
| Whole Body Imaging | 4 | 2024 | 114 | 0.190 |
Why?
|
| Foot Injuries | 1 | 2020 | 13 | 0.190 |
Why?
|
| Radiation Injuries | 2 | 2020 | 1411 | 0.190 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 1 | 2019 | 10 | 0.180 |
Why?
|
| Activities of Daily Living | 1 | 2023 | 552 | 0.180 |
Why?
|
| Anterior Cruciate Ligament Injuries | 1 | 2020 | 52 | 0.180 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2020 | 51 | 0.180 |
Why?
|
| Adolescent | 13 | 2024 | 31252 | 0.180 |
Why?
|
| Neoplasms | 3 | 2024 | 15193 | 0.180 |
Why?
|
| Artifacts | 2 | 2023 | 532 | 0.180 |
Why?
|
| Spinal Cord Diseases | 1 | 2020 | 90 | 0.180 |
Why?
|
| Bone Resorption | 2 | 2019 | 138 | 0.180 |
Why?
|
| Hemangiosarcoma | 1 | 2022 | 234 | 0.180 |
Why?
|
| Digestive System Neoplasms | 1 | 2020 | 82 | 0.180 |
Why?
|
| Pain Measurement | 4 | 2018 | 953 | 0.170 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 6009 | 0.170 |
Why?
|
| Leukemia, Plasma Cell | 1 | 2019 | 42 | 0.170 |
Why?
|
| Sclerosis | 1 | 2019 | 84 | 0.170 |
Why?
|
| Colitis | 1 | 2022 | 340 | 0.170 |
Why?
|
| Decompression, Surgical | 2 | 2016 | 143 | 0.170 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2024 | 1648 | 0.170 |
Why?
|
| Deltoid Muscle | 1 | 2018 | 4 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2022 | 15862 | 0.170 |
Why?
|
| Knee | 1 | 2018 | 33 | 0.170 |
Why?
|
| Stereotaxic Techniques | 2 | 2016 | 172 | 0.160 |
Why?
|
| Bone Transplantation | 1 | 2019 | 134 | 0.160 |
Why?
|
| Search Engine | 1 | 2018 | 21 | 0.160 |
Why?
|
| Osteogenesis | 2 | 2019 | 271 | 0.160 |
Why?
|
| Musculoskeletal System | 1 | 2018 | 35 | 0.160 |
Why?
|
| Thrombophlebitis | 1 | 2018 | 31 | 0.160 |
Why?
|
| Hip Fractures | 1 | 2019 | 76 | 0.160 |
Why?
|
| Shoulder Injuries | 1 | 2018 | 37 | 0.160 |
Why?
|
| Shoulder Pain | 1 | 2018 | 31 | 0.160 |
Why?
|
| Probability | 1 | 2020 | 866 | 0.160 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 388 | 0.150 |
Why?
|
| Postoperative Care | 2 | 2019 | 739 | 0.150 |
Why?
|
| Pelvic Bones | 1 | 2018 | 95 | 0.150 |
Why?
|
| Spondylarthropathies | 1 | 2017 | 4 | 0.150 |
Why?
|
| Heart Neoplasms | 1 | 2020 | 214 | 0.150 |
Why?
|
| Sacroiliitis | 1 | 2017 | 4 | 0.150 |
Why?
|
| United States | 11 | 2020 | 15433 | 0.150 |
Why?
|
| Asphyxia | 1 | 2017 | 21 | 0.150 |
Why?
|
| Ultrasonography | 2 | 2021 | 1863 | 0.150 |
Why?
|
| Leiomyoma | 1 | 2018 | 145 | 0.150 |
Why?
|
| Adipocytes | 1 | 2019 | 305 | 0.150 |
Why?
|
| False Positive Reactions | 2 | 2015 | 355 | 0.150 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2017 | 52 | 0.150 |
Why?
|
| Back Pain | 1 | 2017 | 61 | 0.150 |
Why?
|
| Cellular Reprogramming | 1 | 2019 | 189 | 0.150 |
Why?
|
| Pyrrolidinones | 1 | 2017 | 61 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2017 | 419 | 0.150 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2017 | 72 | 0.150 |
Why?
|
| Anthracyclines | 3 | 2024 | 331 | 0.150 |
Why?
|
| Fibula | 1 | 2018 | 146 | 0.150 |
Why?
|
| Denosumab | 1 | 2017 | 68 | 0.150 |
Why?
|
| Simulation Training | 1 | 2019 | 149 | 0.150 |
Why?
|
| Neuronavigation | 1 | 2017 | 47 | 0.150 |
Why?
|
| Thymidine Phosphorylase | 1 | 2016 | 23 | 0.150 |
Why?
|
| Follow-Up Studies | 11 | 2021 | 14889 | 0.140 |
Why?
|
| Disease Progression | 3 | 2021 | 6682 | 0.140 |
Why?
|
| Neuroectodermal Tumors | 1 | 2016 | 35 | 0.140 |
Why?
|
| Arthritis, Infectious | 1 | 2017 | 68 | 0.140 |
Why?
|
| Databases, Factual | 1 | 2024 | 2218 | 0.140 |
Why?
|
| ROC Curve | 1 | 2020 | 1183 | 0.140 |
Why?
|
| Stomach Neoplasms | 2 | 2019 | 2278 | 0.140 |
Why?
|
| Body Composition | 1 | 2019 | 595 | 0.140 |
Why?
|
| Pneumonia | 1 | 2022 | 751 | 0.140 |
Why?
|
| Teaching | 1 | 2018 | 243 | 0.140 |
Why?
|
| DNA Copy Number Variations | 1 | 2023 | 1516 | 0.140 |
Why?
|
| Soft Tissue Infections | 1 | 2017 | 102 | 0.140 |
Why?
|
| Joint Instability | 1 | 2016 | 88 | 0.140 |
Why?
|
| Image Enhancement | 1 | 2019 | 561 | 0.140 |
Why?
|
| Cyst Fluid | 1 | 2015 | 21 | 0.130 |
Why?
|
| Knee Joint | 1 | 2016 | 161 | 0.130 |
Why?
|
| Incidence | 5 | 2019 | 5673 | 0.130 |
Why?
|
| Knee Injuries | 1 | 2015 | 63 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2024 | 1350 | 0.130 |
Why?
|
| Transcriptome | 2 | 2021 | 1859 | 0.130 |
Why?
|
| Musculoskeletal Diseases | 1 | 2016 | 81 | 0.130 |
Why?
|
| Peripheral Nerve Injuries | 1 | 2015 | 60 | 0.130 |
Why?
|
| Multiple Trauma | 1 | 2015 | 64 | 0.130 |
Why?
|
| Gastric Mucosa | 1 | 2019 | 613 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 992 | 0.130 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2018 | 273 | 0.130 |
Why?
|
| Intestinal Neoplasms | 1 | 2016 | 189 | 0.130 |
Why?
|
| Radiotherapy Dosage | 6 | 2019 | 3842 | 0.130 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2017 | 297 | 0.120 |
Why?
|
| Osteomyelitis | 1 | 2017 | 236 | 0.120 |
Why?
|
| Thoracic Wall | 1 | 2016 | 183 | 0.120 |
Why?
|
| Aftercare | 1 | 2016 | 259 | 0.120 |
Why?
|
| Adipose Tissue | 1 | 2019 | 769 | 0.120 |
Why?
|
| Prospective Studies | 6 | 2022 | 12873 | 0.120 |
Why?
|
| Radiation Tolerance | 1 | 2017 | 629 | 0.120 |
Why?
|
| Lung | 1 | 2005 | 3151 | 0.120 |
Why?
|
| Phenylurea Compounds | 1 | 2017 | 580 | 0.120 |
Why?
|
| Cysts | 1 | 2015 | 197 | 0.120 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2016 | 2326 | 0.120 |
Why?
|
| Cryosurgery | 1 | 2015 | 167 | 0.120 |
Why?
|
| Femoral Neoplasms | 1 | 2014 | 64 | 0.120 |
Why?
|
| Quinolines | 1 | 2017 | 383 | 0.120 |
Why?
|
| Hip Dislocation | 1 | 2014 | 27 | 0.120 |
Why?
|
| Cancer Pain | 1 | 2018 | 312 | 0.120 |
Why?
|
| Pyridines | 2 | 2017 | 1244 | 0.110 |
Why?
|
| Papilloma | 1 | 2013 | 74 | 0.110 |
Why?
|
| Thoracic Neoplasms | 1 | 2016 | 337 | 0.110 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 2864 | 0.110 |
Why?
|
| Dexamethasone | 4 | 2019 | 1450 | 0.110 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2022 | 1249 | 0.110 |
Why?
|
| Pain Management | 1 | 2018 | 668 | 0.110 |
Why?
|
| Spinal Cord Injuries | 1 | 2016 | 374 | 0.110 |
Why?
|
| Neurofibromatosis 1 | 1 | 2014 | 144 | 0.110 |
Why?
|
| Child | 7 | 2023 | 29154 | 0.110 |
Why?
|
| Hamartoma | 1 | 2013 | 115 | 0.110 |
Why?
|
| Survival Rate | 7 | 2020 | 12221 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
| Hemangioma | 1 | 2013 | 154 | 0.100 |
Why?
|
| Extremities | 1 | 2013 | 303 | 0.100 |
Why?
|
| Nervous System Diseases | 1 | 2016 | 500 | 0.100 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 671 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2020 | 6207 | 0.100 |
Why?
|
| Spermatic Cord Torsion | 1 | 2011 | 9 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 5319 | 0.100 |
Why?
|
| Carcinoid Tumor | 1 | 2013 | 280 | 0.100 |
Why?
|
| Cholecystitis, Acute | 1 | 2011 | 17 | 0.100 |
Why?
|
| Carcinoma, Small Cell | 1 | 2013 | 408 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 1209 | 0.090 |
Why?
|
| Surgical Flaps | 1 | 2016 | 927 | 0.090 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 1258 | 0.090 |
Why?
|
| Lung Neoplasms | 4 | 2020 | 11538 | 0.090 |
Why?
|
| Disease-Free Survival | 5 | 2021 | 10001 | 0.090 |
Why?
|
| Survival Analysis | 5 | 2019 | 9180 | 0.090 |
Why?
|
| Neoplasm Staging | 4 | 2019 | 13658 | 0.090 |
Why?
|
| Doxorubicin | 3 | 2023 | 3005 | 0.090 |
Why?
|
| Pain, Postoperative | 1 | 2014 | 610 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2019 | 6869 | 0.080 |
Why?
|
| Radiography | 1 | 2013 | 1904 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2018 | 16273 | 0.080 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2011 | 340 | 0.080 |
Why?
|
| Registries | 1 | 2015 | 2170 | 0.080 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 1664 | 0.080 |
Why?
|
| Acute Coronary Syndrome | 1 | 2011 | 259 | 0.080 |
Why?
|
| Hip Joint | 1 | 2007 | 54 | 0.080 |
Why?
|
| Rats, Inbred WKY | 2 | 2004 | 110 | 0.080 |
Why?
|
| Rats, Inbred SHR | 2 | 2004 | 113 | 0.080 |
Why?
|
| Algorithms | 2 | 2022 | 3890 | 0.080 |
Why?
|
| Pulmonary Embolism | 1 | 2011 | 329 | 0.070 |
Why?
|
| Medical Oncology | 1 | 2016 | 1423 | 0.070 |
Why?
|
| Palliative Care | 1 | 2018 | 2037 | 0.070 |
Why?
|
| Bortezomib | 2 | 2019 | 543 | 0.070 |
Why?
|
| Rats | 3 | 2004 | 6086 | 0.070 |
Why?
|
| Oligopeptides | 2 | 2019 | 429 | 0.070 |
Why?
|
| Analysis of Variance | 3 | 2015 | 2307 | 0.070 |
Why?
|
| Species Specificity | 2 | 2004 | 777 | 0.070 |
Why?
|
| Membrane Potentials | 2 | 2004 | 424 | 0.070 |
Why?
|
| Kidney Neoplasms | 2 | 2016 | 3022 | 0.070 |
Why?
|
| Osteoblasts | 2 | 2019 | 370 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 3552 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 5767 | 0.070 |
Why?
|
| Thyroid Neoplasms | 1 | 2016 | 1866 | 0.070 |
Why?
|
| Medulla Oblongata | 1 | 2005 | 45 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 2403 | 0.060 |
Why?
|
| 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 2004 | 8 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2019 | 665 | 0.060 |
Why?
|
| Photoperiod | 1 | 2004 | 31 | 0.060 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2019 | 604 | 0.060 |
Why?
|
| Potassium Channels, Calcium-Activated | 1 | 2004 | 13 | 0.060 |
Why?
|
| Feedback | 1 | 2005 | 198 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 5539 | 0.060 |
Why?
|
| Infant | 2 | 2018 | 13310 | 0.060 |
Why?
|
| Titanium | 1 | 2023 | 61 | 0.060 |
Why?
|
| Ion Channel Gating | 1 | 2004 | 141 | 0.060 |
Why?
|
| Ketones | 1 | 2023 | 54 | 0.060 |
Why?
|
| Animals | 7 | 2023 | 59536 | 0.060 |
Why?
|
| Treatment Failure | 2 | 2017 | 1391 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2004 | 2063 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2005 | 1529 | 0.050 |
Why?
|
| S100 Proteins | 1 | 2023 | 181 | 0.050 |
Why?
|
| Remission Induction | 2 | 2019 | 3569 | 0.050 |
Why?
|
| Femur | 1 | 2023 | 158 | 0.050 |
Why?
|
| Down-Regulation | 2 | 2019 | 2074 | 0.050 |
Why?
|
| Potassium | 1 | 2003 | 329 | 0.050 |
Why?
|
| Disease Management | 2 | 2020 | 1052 | 0.050 |
Why?
|
| Synaptic Transmission | 1 | 2005 | 443 | 0.050 |
Why?
|
| Sodium | 1 | 2003 | 353 | 0.050 |
Why?
|
| Retinal Ganglion Cells | 1 | 2003 | 144 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 3578 | 0.050 |
Why?
|
| Cyclophosphamide | 2 | 2019 | 3001 | 0.050 |
Why?
|
| Dopamine | 1 | 2003 | 312 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2019 | 2450 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2016 | 925 | 0.050 |
Why?
|
| Patient Selection | 2 | 2020 | 2055 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 10331 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2018 | 6550 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2023 | 726 | 0.050 |
Why?
|
| Polyethylene Glycols | 1 | 2023 | 615 | 0.040 |
Why?
|
| Recurrence | 2 | 2019 | 4758 | 0.040 |
Why?
|
| Logistic Models | 2 | 2019 | 3441 | 0.040 |
Why?
|
| Health Status | 1 | 2023 | 590 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2016 | 4557 | 0.040 |
Why?
|
| Behavior, Animal | 1 | 2003 | 709 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 4314 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2004 | 4938 | 0.040 |
Why?
|
| Salivary Glands | 1 | 2019 | 130 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 4298 | 0.040 |
Why?
|
| Adipokines | 1 | 2019 | 96 | 0.040 |
Why?
|
| Immunotherapy | 2 | 2022 | 3341 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 5437 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 14289 | 0.040 |
Why?
|
| beta Catenin | 1 | 2022 | 688 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2018 | 77 | 0.040 |
Why?
|
| Sp1 Transcription Factor | 1 | 2019 | 188 | 0.040 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2019 | 160 | 0.040 |
Why?
|
| PPAR gamma | 1 | 2019 | 229 | 0.040 |
Why?
|
| Retreatment | 1 | 2019 | 452 | 0.040 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 15694 | 0.040 |
Why?
|
| Neurosurgical Procedures | 1 | 2023 | 609 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2018 | 100 | 0.040 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2019 | 245 | 0.040 |
Why?
|
| Contraindications, Procedure | 1 | 2017 | 8 | 0.040 |
Why?
|
| Methylation | 1 | 2019 | 597 | 0.040 |
Why?
|
| Curettage | 1 | 2017 | 22 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 4988 | 0.040 |
Why?
|
| Risk Factors | 3 | 2023 | 17523 | 0.040 |
Why?
|
| Veins | 1 | 2018 | 157 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2018 | 216 | 0.040 |
Why?
|
| Glycolysis | 1 | 2020 | 519 | 0.040 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2020 | 565 | 0.040 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2016 | 30 | 0.040 |
Why?
|
| Sp7 Transcription Factor | 1 | 2016 | 27 | 0.040 |
Why?
|
| Age Factors | 2 | 2017 | 5377 | 0.040 |
Why?
|
| Spinal Cord | 1 | 2020 | 690 | 0.040 |
Why?
|
| Receptors, CXCR4 | 1 | 2018 | 269 | 0.040 |
Why?
|
| Tibia | 1 | 2017 | 131 | 0.040 |
Why?
|
| Interferon Regulatory Factors | 1 | 2016 | 76 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2016 | 160 | 0.040 |
Why?
|
| Osteolysis | 1 | 2016 | 80 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2019 | 864 | 0.030 |
Why?
|
| Prednisone | 1 | 2019 | 984 | 0.030 |
Why?
|
| Time Factors | 3 | 2020 | 12926 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2017 | 259 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2016 | 175 | 0.030 |
Why?
|
| Fluoroscopy | 1 | 2017 | 232 | 0.030 |
Why?
|
| RANK Ligand | 1 | 2016 | 119 | 0.030 |
Why?
|
| Causality | 1 | 2016 | 178 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2020 | 1021 | 0.030 |
Why?
|
| Osteoclasts | 1 | 2016 | 165 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 1290 | 0.030 |
Why?
|
| Exercise | 1 | 2023 | 1183 | 0.030 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2019 | 475 | 0.030 |
Why?
|
| Anesthesia, General | 1 | 2017 | 239 | 0.030 |
Why?
|
| Patient Positioning | 1 | 2017 | 195 | 0.030 |
Why?
|
| Injury Severity Score | 1 | 2015 | 237 | 0.030 |
Why?
|
| Heterozygote | 1 | 2018 | 1020 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 829 | 0.030 |
Why?
|
| Indazoles | 1 | 2016 | 297 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.030 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2017 | 304 | 0.030 |
Why?
|
| Vincristine | 1 | 2019 | 1511 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2015 | 231 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2022 | 1154 | 0.030 |
Why?
|
| Radiation Protection | 1 | 2015 | 205 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 5178 | 0.030 |
Why?
|
| CpG Islands | 1 | 2016 | 633 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 1914 | 0.030 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2016 | 310 | 0.030 |
Why?
|
| Image-Guided Biopsy | 1 | 2016 | 327 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2020 | 1656 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2021 | 1360 | 0.030 |
Why?
|
| Students, Medical | 1 | 2019 | 399 | 0.030 |
Why?
|
| Rituximab | 1 | 2019 | 1528 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 2291 | 0.030 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2015 | 255 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 1022 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2018 | 1245 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2018 | 1046 | 0.030 |
Why?
|
| Neutropenia | 1 | 2017 | 968 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2019 | 14551 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2016 | 661 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 3890 | 0.030 |
Why?
|
| Quality of Life | 2 | 2016 | 4532 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 3101 | 0.030 |
Why?
|
| Histones | 1 | 2019 | 1466 | 0.030 |
Why?
|
| Research Design | 1 | 2019 | 1544 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 2292 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 3251 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2015 | 1014 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 3472 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2015 | 785 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2014 | 629 | 0.020 |
Why?
|
| Mutation | 2 | 2022 | 15179 | 0.020 |
Why?
|
| Fatigue | 1 | 2017 | 1239 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1945 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 2231 | 0.020 |
Why?
|
| Mice | 2 | 2023 | 34495 | 0.020 |
Why?
|
| Acute Disease | 1 | 2015 | 2422 | 0.020 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2020 | 1237 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 1533 | 0.020 |
Why?
|
| Radiotherapy, Conformal | 1 | 2015 | 902 | 0.020 |
Why?
|
| Comorbidity | 1 | 2016 | 2352 | 0.020 |
Why?
|
| Pregnancy | 1 | 2022 | 7573 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 4367 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 1303 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 5159 | 0.020 |
Why?
|
| Pain | 1 | 2017 | 1658 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2019 | 4078 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2016 | 1471 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2016 | 1823 | 0.020 |
Why?
|
| Hypertension | 1 | 2017 | 1503 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2017 | 2370 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 5047 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 4975 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 2992 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2016 | 2669 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 7222 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 5687 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8223 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2014 | 1371 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 5112 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 4113 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2016 | 3518 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 8865 | 0.010 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2003 | 132 | 0.010 |
Why?
|
| Random Allocation | 1 | 2003 | 703 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2019 | 11965 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2003 | 5637 | 0.010 |
Why?
|
| Neurons | 1 | 2003 | 2287 | 0.010 |
Why?
|